IP Library Granted Patent US 11,548,944
Granted Patent B2
US 11,548,944 · App. 17/360,809 · Granted Jan 10, 2023

Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof

Inventors: Stephen James Moore (Danville, CA); Margaret Thy Luu Nguyen (San Francisco, CA); Daniel Robert Hostetter (Palo Alto, CA); Olga Vasiljeva (Cupertino, CA); Jason Gary Sagert (San Mateo, CA); Jonathan Alexander Terrett (Cupertino, CA); James William West (Bend, OR)
Assignee: CytomX Therapeutics, Inc.
C07K16/28A61K38/05A61K47/6849A61K47/6851A61K49/0058C07K7/08C07K14/00C07K16/2863C07K16/2896C07K16/40A61K2039/505A61K2039/507C07K2317/51C07K2317/515C07K2317/92C07K2319/50C07K2319/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,548,944
App. No.
17/360,809
Granted
Jan 10, 2023
Kind
B2
Abstract

The invention relates generally to polypeptides that include at least a first cleavable moiety (CM1) that is a substrate for at least one matrix metalloprotease (MMP) and at least a second cleavable moiety (CM2) that is a substrate for at least one serine protease (SP), to activatable antibodies and other larger molecules that include these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease, and to methods of making and using these polypeptides that include at least a CM1 that is a substrate for at least one MMP protease and at least a CM2 that is a substrate for at least one SP protease in a variety of therapeutic, diagnostic and prophylactic indications.

Claims (11)

1. An isolated polypeptide comprising a CM1-CM2 substrate comprising a first cleavable moiety (CM1) that is a substrate for a matrix metalloprotease (MMP) and a second cleavable moiety (CM2) that is a substrate for a serine protease (SP), wherein the CM1-CM2 substrate comprises the amino acid sequence

selected from the group consisting of SEQ ID NOs: 483-490 and 555.

2. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 483.

3. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 484.

4. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 485.

5. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 486.

6. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 487.

7. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 488.

8. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 489.

9. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 490.

10. The isolated polypeptide of claim 1 , wherein the CM1-CM2 substrate comprises the amino acid sequence of SEQ ID NO: 555.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2021
From: MOORE, STEPHEN JAMES; NGUYEN, MARGARET THY LUU; HOSTETTER, DANIEL ROBERT; VASILJEVA, OLGA; SAGERT, JASON GARY; TERRETT, JONATHAN ALEXANDER; WEST, JAMES WILLIAM
To: CYTOMX THERAPEUTICS, INC.
Reel/Frame 056707/0274 →
Continuity (7)
Division 15002131 · Jan 20, 2016
Provisional Application 62278713 · Jan 14, 2016
Provisional Application 62277771 · Jan 12, 2016
Provisional Application 62258015 · Nov 20, 2015
Provisional Application 62105490 · Jan 20, 2015
Related Publication 20210355208A1 · Nov 18, 2021
Related Publication 20220380453A9 · Dec 1, 2022